CoChat

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma

Open access
Ghosh, Arindam P., Marshall, Christopher B., Coric, Tatjana, Shim, Eun-hee, Kirkman, Richard, Ballestas, Mary E., Ikura, Mitsuhiko, Bjornsti, Mary-Ann, Sudarshan, Sunil · 2015 · Oncotarget
Cited by 77

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

// Arindam P. Ghosh 1 , Christopher B. Marshall 4 , Tatjana Coric 2 , Eun-hee Shim 1 , Richard Kirkman 1 , Mary E. Ballestas 3 , Mitsuhiko Ikura 4 , Mary-Ann Bjornsti 2 and Sunil Sudarshan 1 1 Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama, USA 2 Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama, USA 3 Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA 4 Department of Medical Biophysics, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada Correspondence to: Sunil Sudarshan, email: // Keywords : mTOR, RHEB, rapamycin, renal cancer, mutations Received : June 08, 2015 Accepted : July 03, 2015 Published : July 22, 2015 Abstract Aberrations in the mTOR (mechanistic target of rapamycin) axis are frequently reported in cancer. Using publicly available tumor genome sequencing data, we identified several point mutations in MTOR and its upstream regulator RHEB (Ras homolog enriched in brain) in patients with clear cell renal cell carcinoma (ccRCC), the most common histology of kidney cancer. Interestingly, we found a prominent cluster of hyperactivating mutations in the FAT (FRAP-ATM-TTRAP) domain of mTOR in renal cell carcinoma that led to an increase in both mTORC1 and mTORC2 activities and led to an increased proliferation of cells. Several of the FAT domain mutants demonstrated a decreased binding of DEPTOR (DEP domain containing mTOR-interacting protein), while a subset of these mutations showed altered binding of the negative regulator PRAS40 (proline rich AKT substrate 40). We also identified a recurrent mutation in RHEB in ccRCC patients that leads to an increase in mTORC1 activity. In vitro characterization of this RHEB mutation revealed that this mutant showed considerable resistance to TSC2 (Tuberous Sclerosis 2) GAP (GTPase activating protein) activity, though its interaction with TSC2 remained unaltered. Mutations in the FAT domain of MTOR and in RHEB remained sensitive to rapamycin, though several of these mutations demonstrated residual mTOR kinase activity after treatment with rapamycin at clinically relevant doses. Overall, our data suggests that point mutations in the mTOR pathway may lead to downstream mTOR hyperactivation through multiple different mechanisms to confer a proliferative advantage to a tumor cell.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4963

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 77

Metadata

Authors
Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E.-H., Kirkman, R., Ballestas, M. E., Ikura, M., Bjornsti, M.-A., & Sudarshan, S.
Venue
Oncotarget
Published
2015-07-20
Volume
6
Issue
20
Pages
17895-17910
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1894437547
Cited by
77
References
18
FWCI
4.37
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. https://app.cochat.ai/papers/10.18632/oncotarget.4963
The paper
Ghosh, A. P., Marshall, C. B., Coric, T., Shim, E.-H., Kirkman, R., Ballestas, M. E., Ikura, M., Bjornsti, M.-A., & Sudarshan, S. (2015). Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.4963

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.